| Dhaka | Global animal health company Vaxxinova has announced that its poultry vaccine Vaxxon® SHS has been named the 2025 Animal Health Award winner for Best New Food Animal Product, presented by S&P Global. The recognition underscores the company’s focus on scientific innovation and close collaboration with poultry producers worldwide.
Breakthrough in Poultry Health Vaxxon® SHS is a lyophilized live attenuated Avian Metapneumovirus (aMPV) vaccine developed to protect poultry against Swollen Head Syndrome (SHS). According to the company, the vaccine has demonstrated field effectiveness for more than 20 years in multiple poultry production systems outside the United States. In 2025, the United States Department of Agriculture granted Vaxxinova the first-ever U.S. approval for the importation of a live vaccine for food-producing animals, marking a significant regulatory milestone for the sector. Why the Product Stood Out Award judges cited several strengths behind the selection, including:
Value for Poultry Producers Producers using Vaxxon® SHS have reported notable improvements following vaccination programs, the company said. Vaxxinova also provides an inactivated aMPV vaccine, enabling the widely recommended live-prime and inactivated-boost strategy sought by the poultry industry. Company Perspective Vaxxinova described the award as a reflection of its position as an agile global organization working closely with veterinarians and producers to deliver practical and effective vaccine solutions. Looking Ahead The recognition of Vaxxon® SHS as the 2025 Best New Food Animal Product reinforces the company’s commitment to advancing poultry health through innovation and scientific excellence. Vaxxinova expressed appreciation to its customers for their continued trust and to S&P Global for the industry recognition. |
